Kamada (KMDA) Payout Ratio (2025 - 2026)
Kamada's (KMDA) quarterly Payout Ratio came in at 1.3 in Q2 2026, up 53.55% on a YoY basis from 0.84 in Q2 2025, and down 159.82% quarter-over-quarter from 2.17 in Q1 2026.
Powered by 
Analysis
Kamada (KMDA) Payout Ratio (2025 - 2026) Analysis & Trends
Kamada (KMDA) has reported Payout Ratio for 2 consecutive years, with 1.3 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Payout Ratio rose 53.55% year-over-year to 1.3; the trailing twelve-month figure through Mar 2026 stood at 0.12 (changed N/A YoY), and the FY2025 full-year result was 0.43, changed N/A from the prior year.
- Payout Ratio fell to 1.3 in Q2 2026 per KMDA's latest filing, from 2.17 in the prior quarter.
- Across five years, Payout Ratio topped out at 2.17 in Q1 2026 and bottomed at 2.79 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.30 Bn | 197.31 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.97 Bn | 177.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.27 Bn | 124.42 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.93 Bn | 74.93 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.53 Bn | 56.35 Bn | 1.37 Bn |
| 6 | Moderna | 54.27 Bn | 49.13 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.46 Bn | 31.15 Bn | 992.69 Mn |
| 8 | Biogen | 31.16 Bn | 29.88 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.08 Bn | 30.08 Bn | 1.16 Mn |
| 10 | Kamada | 473.85 Mn | 403.72 Mn | 22.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.30 |
| Mar 31, 2026 | 2.17 |
| Jun 30, 2025 | -2.79 |
| Mar 31, 2025 | 1.25 |